Lumos Diagnostics Advances Capital Management by Exercising 704,351 Options, Issuing 431,229 Shares on ASX

Conversion of Three Separate Option Classes Under LTIP

Between 23 and 26 June 2026, Lumos Diagnostics converted options from three distinct classes as part of its employee incentive framework. The first tranche involved 178,351 options with a $0.0576 strike price expiring 31 August 2026. This tranche was exercised through a mix of cash settlement (36,821 options) and cashless net settlement (141,530 options), valued at approximately $0.1230 per security per LTIP guidelines. This resulted in 112,368 ordinary shares issued on 24 July 2026, now pending ASX quotation.

The second tranche comprised 225,000 options at a $0.0125 strike price expiring 10 August 2028, fully exercised via cashless net settlement with an estimated valuation of $0.0141 per option. This exercise yielded 202,493 shares issued on the same date. The third and largest tranche converted 301,000 options with a $0.0687 strike price expiring 18 January 2029. Key management personnel and associates participated in at least one tranche, underscoring senior leadership’s involvement in the incentive exercises.

Capital Base Growth Through Employee Incentive Conversions

The option exercises represent a significant capital management milestone, expanding Lumos Diagnostics’ ordinary share capital by 431,229 shares. The LTIP’s dual settlement options allowed flexibility, enabling some holders to pay cash while others utilized cashless net settlement to offset exercise costs against intrinsic option value. This approach facilitated broad participation across employees and management.

Approved by shareholders on 14 November 2024, the LTIP framework governs vesting, settlement, and governance of these conversions. The clustered exercise dates in late June 2026 indicate coordinated activity rather than isolated transactions. The newly issued shares carry equal rights with existing ordinary shares, ensuring uniform voting, dividend, and liquidation entitlements.

ASX Quotation Application and Compliance

Lumos Diagnostics applied for ASX quotation of the 431,229 ordinary shares on 28 July 2026, two trading days after issuance on 24 July 2026, adhering to ASX procedural timelines. These fully paid shares will trade under the existing ticker LDX upon approval, maintaining consistency with the current share register. No disclosed conditions or restrictions on quotation were noted.

The exercised options were previously unquoted and held outside the main capital pool, and their conversion simplifies the company’s capital structure by reducing outstanding derivative securities. While not all options in each class have been exercised, further conversions may occur ahead of their expiration dates.

Settlement Methods and Valuation Details

The LTIP’s design allowed two settlement methods during the exercises. In the first tranche, 36,821 options were cash-settled at $0.0576 strike price, while 141,530 were net settled cashlessly using a valuation of $0.1230 per security. The second tranche’s 225,000 options were entirely cashless net settled, valued at $0.0141 each. The third tranche employed net settlement per plan rules, though specific valuations were not disclosed. These varied methods reflect a flexible incentive plan accommodating different participant needs.

Shareholder-Approved Framework Driving Option Exercises

The authority for these option conversions stems from shareholder approval granted on 14 November 2024, establishing the LTIP’s governance, vesting schedules, and settlement protocols. The timing of these large-scale exercises in June 2026 suggests that vesting milestones were met. While key management personnel participation was confirmed, the announcement did not specify the breakdown of exercised options by management versus other employees.

Concentrated Exercise Window and Administrative Timeline

The four-day exercise window from 23 to 26 June 2026 indicates a coordinated or scheduled exercise period under LTIP rules, facilitating orderly capital management. The issuance of shares on 24 July 2026 allowed for necessary administrative processing and ASX preparation. The company did not disclose cash proceeds from cash-settled exercises.

Impact on Share Capital and Dilution Considerations

Conversion of 704,351 options into 431,229 shares expands Lumos Diagnostics’ ordinary capital base meaningfully, though the precise dilution impact depends on the pre-existing share count, which was not disclosed. The ratio of options exercised to shares issued (approximately 1.63:1) reflects net settlement calculations. Outstanding options remain in at least two classes, indicating potential for future dilution events.

ASX Listing Rules Adherence and Reporting Obligations

The quotation application complies with ASX Listing Rules Appendix 2A, covering securities issued from option conversions. The company fulfilled disclosure requirements regarding strike prices, expiration dates, settlement methods, and valuations. The new shares rank equally with existing shares, maintaining shareholder rights.

Lumos Diagnostics remains obligated to maintain accurate securities registers, disclose significant option conversions, and update shareholders on capital management. No changes to dividend policies or share buybacks were announced. Investors should monitor company disclosures for updates on capital strategy and future option exercises.

Strategic LTIP Design and Market Alignment

The LTIP’s multi-tranche structure with varying strike prices from $0.0125 to $0.0687 and expiration dates through January 2029 reflects a staged equity incentive strategy aimed at long-term employee alignment and shareholder value creation. The June 2026 exercise timing may relate to tax planning or market conditions, though the company did not specify triggers or performance conditions.

Valuation estimates used in cashless settlements ($0.1230 and $0.0141) suggest underlying share prices supported in-the-money exercises across all tranches. The announcement did not provide share price history or trading metrics to contextualize option exercise attractiveness.